What it is
Prostamax is a synthetic tetrapeptide bioregulator from the Khavinson literature.
Evidence boundary
Evidence is concentrated in Russian bioregulator and gerontology literature, with limited independent Western replication.
Trial evidence
- PMID 15612551 — The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ.
- PMID 15085253 — Effects of short peptides on lymphocyte chromatin in senile subjects.
- PMID 17152728 — The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats.
- PMID 23221144 — Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro).
Preparation and measurement
Reconstitution: 20 mg vial + 2 mL BAC = 10 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Source cycle | 500 mcg | 5 U (0.05 mL) | Once daily | 3.5 mg/week |
| Source cycle | 750 mcg | 7.5 U (0.075 mL) | Once daily | 5.25 mg/week |
| Source cycle | 1 mg | 10 U (0.1 mL) | Once daily | 7 mg/week |
Source cycle
- Dose
- 500 mcg
- Draw / measure
- 5 U (0.05 mL)
- Frequency
- Once daily
- Weekly total
- 3.5 mg/week
Source cycle
- Dose
- 750 mcg
- Draw / measure
- 7.5 U (0.075 mL)
- Frequency
- Once daily
- Weekly total
- 5.25 mg/week
Source cycle
- Dose
- 1 mg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- Once daily
- Weekly total
- 7 mg/week
Weekly totals apply only during the active phase. This is a reported schedule, not a validated human regimen.
Titration rules
-
The source uses a short daily cycle, not a validated escalation plan.
-
Do not present the rows as a formal dosing standard.
-
No human trial establishes an optimal titration sequence.
-
The regional literature signal
-
Do not mistake this for a standard prostate drug.
-
The absence of strong independent replication
-
Any formulation or route changes that would make the reported schedule no longer comparable
Practical rules
- Keep the interpretation clearly regional.
- Do not use it as prostate-treatment advice.
- Do not mix it with unrelated bioregulators.
- Treat the schedule as a source note, not a care plan.